ArticleESC heart failure2023

Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.

Monika Beles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.